Related Experiment Video
Updated: Aug 2, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Medical research funding may have over-expanded and be due for collapse
1Henry Wellcome Building, University of Newcastle upon Tyne NE1 7RU, UK. bruce.charlton@ncl.ac.uk
Abstract:
The continual and uninterrupted expansion of medical research funding is generally assumed to be a permanent feature of modern societies, but this expectation may turn out to be mistaken. Sciences tend to go through boom and bust phases. Twentieth century physics is an example where huge increases in funding followed an era of scientific breakthroughs. Speculative over-expansion led to diminishing returns on investment, then a collapse in funding. We predict that medicine will follow the same trajectory. After prolonged over-funding of the 'basic-to-applied' model of clinical innovation, and a progressive shift towards Big Science organization, medical research has become increasingly inefficient and ineffective. Although incremental improvements to existing treatment strategies continue, the rate of significant therapeutic breakthroughs has been declining for three decades. Medical science now requires rationalization and modernization. From this perspective, the current level of medical research funding looks like a bubble due to burst.
Related Concept Videos
Drug Discovery: Overview
Clinical Trials: Overview
Drug Regulation
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

